- Home
- ESP vs SKYE Comparison
ESP vs SKYE Comparison
Compare ESP & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESP
- SKYE
- Stock Information
- Founded
- ESP 1928
- SKYE 2012
- Country
- ESP United States
- SKYE United States
- Employees
- ESP N/A
- SKYE N/A
- Industry
- ESP Industrial Machinery/Components
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- ESP Technology
- SKYE Health Care
- Exchange
- ESP Nasdaq
- SKYE Nasdaq
- Market Cap
- ESP 84.1M
- SKYE 80.7M
- IPO Year
- ESP N/A
- SKYE N/A
- Fundamental
- Price
- ESP $26.53
- SKYE $2.43
- Analyst Decision
- ESP
- SKYE Buy
- Analyst Count
- ESP 0
- SKYE 7
- Target Price
- ESP N/A
- SKYE $18.67
- AVG Volume (30 Days)
- ESP 15.2K
- SKYE 136.4K
- Earning Date
- ESP 02-12-2025
- SKYE 03-21-2025
- Dividend Yield
- ESP 3.75%
- SKYE N/A
- EPS Growth
- ESP 31.14
- SKYE N/A
- EPS
- ESP 2.45
- SKYE N/A
- Revenue
- ESP $43,917,522.00
- SKYE N/A
- Revenue This Year
- ESP N/A
- SKYE N/A
- Revenue Next Year
- ESP N/A
- SKYE N/A
- P/E Ratio
- ESP $10.90
- SKYE N/A
- Revenue Growth
- ESP 18.62
- SKYE N/A
- 52 Week Low
- ESP $20.20
- SKYE $2.31
- 52 Week High
- ESP $33.00
- SKYE $17.65
- Technical
- Relative Strength Index (RSI)
- ESP 47.04
- SKYE 40.00
- Support Level
- ESP $25.16
- SKYE $2.40
- Resistance Level
- ESP $26.77
- SKYE $2.88
- Average True Range (ATR)
- ESP 0.87
- SKYE 0.24
- MACD
- ESP 0.06
- SKYE -0.02
- Stochastic Oscillator
- ESP 44.99
- SKYE 3.74
About ESP Espey Mfg. & Electronics Corp.
Espey Manufacturing & Electronics Corp designs, develops, tests, and manufactures specialized military and rugged industrial power supplies and transformers for use in harsh or severe environment applications. Its products and solutions include power converters, power conditioning, high-voltage radar, contract manufacturing, custom engineering, and others. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.